Ptc Therapeutics, INC Form 4 insider transactions

PTC Therapeutics' Chief Business Officer, Eric Pauwels, executed a series of stock option exercises and subsequent share sales totaling 39,850 shares under a pre-arranged 10b5-1 plan.

PTC Therapeutics Director Allan Steven Jacobson sold 1,667 shares of common stock for $50.15 per share on August 28, 2025, executed under a Rule 10b5-1 plan.

A PTC Therapeutics executive exercised stock options and immediately sold the acquired shares under a pre-arranged trading plan.

PTC Therapeutics CEO Matthew B. Klein acquired 75,000 shares through RSU vesting following a regulatory milestone, while selling 10,739 shares to cover tax obligations.

PTC Therapeutics' Chief Financial Officer, Pierre Gravier, sold 2,516 shares of common stock at $49.46 per share to satisfy tax withholding obligations related to RSU vesting.

Mark Boulding, Executive VP and CLO of PTC Therapeutics, exercised stock options and sold shares of common stock on May 15 and 16, 2025, according to a Form 4 filing with the SEC.

CEO Matthew Klein sold 2,804 shares of PTC Therapeutics stock to cover tax obligations related to RSU vesting.

Lee Scott Golden, EVP & Chief Medical Officer of PTC Therapeutics, sold 897 shares of common stock on April 2, 2025, to cover tax obligations related to vesting RSUs.

Eric Pauwels, Chief Business Officer of PTC Therapeutics, sold shares of common stock between March 14 and March 17, 2025, under a pre-arranged 10b5-1 trading plan.

Director Stephanie Okey sold 5,000 shares of PTC Therapeutics (PTCT) common stock at $54 per share on March 13, 2025.

Mark Boulding, Executive VP and CLO of PTC Therapeutics, exercised stock options and sold shares of common stock on March 12, 2025, under a pre-arranged 10b5-1 trading plan.

Mark Boulding, Executive VP and CLO of PTC Therapeutics, reports exercising stock options and selling shares under a pre-arranged 10b5-1 trading plan.

Director Allan Steven Jacobson sold 1,230 shares of PTC Therapeutics (PTCT) common stock at an average price of $51.52 on March 4, 2025.

Christine Marie Utter, SVP, Chief Accounting Officer of PTC Therapeutics, reports selling shares of common stock to cover tax withholding obligations related to RSU vesting.

Pierre Gravier, CFO of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

CEO Eric Pauwels sold shares of PTC Therapeutics stock to cover tax obligations arising from the vesting of restricted stock units (RSUs).

CEO Matthew Klein sold shares of PTC Therapeutics stock to cover tax obligations related to the vesting of restricted stock units.

Lee Scott Golden, EVP & Chief Medical Officer of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to RSU vesting.

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to RSU vesting.

Neil Gregory Almstead, Chief Technical Operations Officer of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to RSU vesting.

Christine Marie Utter, SVP and Chief Accounting Officer of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).

CEO Eric Pauwels sold shares of PTC Therapeutics to cover tax obligations related to the vesting of restricted stock units (RSUs).

CEO Matthew B. Klein of PTC Therapeutics sold shares of common stock on January 7th and 8th, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Lee Scott Golden, EVP & Chief Medical Officer of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units (RSUs).

Neil Gregory Almstead, Chief Technical Operations Officer of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units (RSUs).

Director Alethia Young acquired 4,000 shares of common stock and 8,800 stock options in PTC Therapeutics on January 3, 2025.

Director Jerome B. Zeldis acquired 4,000 shares of common stock and 8,800 stock options in PTC Therapeutics on January 3, 2025.

Director Glenn Steele Jr. of PTC Therapeutics acquired 4,000 shares of common stock and 8,800 stock options on January 3, 2025.

Director David P. Southwell acquired 4,000 shares and 8,800 stock options in PTC Therapeutics on January 3, 2025, according to a recent SEC filing.